AC Immune SA (NAS:ACIU)
$ 3.18 -0.23 (-6.74%) Market Cap: 314.50 Mil Enterprise Value: 202.50 Mil PE Ratio: 0 PB Ratio: 1.93 GF Score: 43/100

AC Immune SA at Jefferies London Healthcare Conference Transcript

Nov 15, 2022 / 08:00AM GMT
Release Date Price: $2.61 (-5.43%)
Peter Welford
Jefferies & Co. - Analyst

Good morning. I think this is the first presentation in this track, so, I welcome you all to the Jefferies 2022 Healthcare Conference in London. Because you don't know me, my name is Peter Welford, I have AC Immune, today, the CEO, Andrea Pfeifer.

Andrea's going to walk through a few slides, and give you a background as an intro to the company, and then, we'll go to Q&A. As usual, if anyone in the audience has any questions, please raise your hand. We have dozen who would love some participation, of now -- I'll just continue in the usual vein.

And with that, over to Andrea, and thank you very much.

Andrea Pfeifer
AC Immune SA - CEO, Co-Founder, Director

Good morning. Thank you for joining. I'm happy to speak to you about AC Immune company, pioneering precision medicine in neurodegenerative diseases.

Today, I will give at the beginning, just a short overview of our company, followed by an update on the pipeline, and our upcoming milestones. So -- What you will see later, AC Immune

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot